Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
SEATTLE, Wash. & VENLO, the Netherlands, February 19, 2026--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and ...
Healthcare Asia Magazine on MSN
Lucence, DXD Hub, and NCCS launch $6m UNITED 2.0 cancer test
The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted ...
Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that it is adding a new AI-powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results